TABLE 2.

Major trials of coxibs versus placebo

Trial	Population	Regimen	Follow-up	Serious cardiovascular events
APPROVe (6)	2586 patients with history of colorectal adenoma	Rofecoxib (R) 25 mg/day vs placebo (Pl)	Mean R=2.4 years, Pl=2.6 years	Serious thrombotic events: R=1.50%/year, Pl=0.78%/year, HR=1.92 (P=0.008)
APC (7)	2035 patients with history of colorectal adenoma	Celecoxib (C) 400 mg or 800 mg/day vs Pl	Range 2.8–3.1 years	Composite of cardiovascular death, myocardial infarction, stroke or heart failure: C=0.96%/year, Pl=0.34%/year, RR=2.8 (P=0.01)
Nussmeier et al (8)	1671 patients immediately after CABG surgery	Parecoxib (P) IV for 3 days, then valdecoxib (V) for 7 days vs Pl IV, then V vs Pl IV, then Pl po	30 days	Cardiovascular events: P or V=1.62% in 1 month (P=0.5), RR=2.9 (P=0.08)

APC Adenoma Prevention with Celecoxib; APPROVe Adenomatous Polyp PRevention On Vioxx; CABG Coronary artery bypass graft; HR Hazard ratio; IV Intravenous; po By mouth